HK1143992A1 - Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatment - Google Patents
Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatmentInfo
- Publication number
- HK1143992A1 HK1143992A1 HK10110333.3A HK10110333A HK1143992A1 HK 1143992 A1 HK1143992 A1 HK 1143992A1 HK 10110333 A HK10110333 A HK 10110333A HK 1143992 A1 HK1143992 A1 HK 1143992A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- adenovirus
- mutations
- endoplasmic reticulum
- protein
- reticulum retention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200700665 | 2007-03-14 | ||
PCT/EP2008/052960 WO2008110579A2 (en) | 2007-03-14 | 2008-03-12 | Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatment. |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1143992A1 true HK1143992A1 (en) | 2011-01-21 |
Family
ID=39722592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10110333.3A HK1143992A1 (en) | 2007-03-14 | 2010-11-04 | Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatment |
Country Status (11)
Country | Link |
---|---|
US (1) | US8974777B2 (xx) |
EP (1) | EP2137301B1 (xx) |
JP (2) | JP5746823B2 (xx) |
CN (1) | CN101702918B (xx) |
AT (1) | ATE510907T1 (xx) |
CA (1) | CA2680659C (xx) |
DK (1) | DK2137301T3 (xx) |
ES (1) | ES2367227T3 (xx) |
HK (1) | HK1143992A1 (xx) |
PT (1) | PT2137301E (xx) |
WO (1) | WO2008110579A2 (xx) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
CN104946602A (zh) * | 2015-06-11 | 2015-09-30 | 华中科技大学同济医学院附属同济医院 | 具有肿瘤组织靶向性和抑癌基因修复性的重组溶瘤腺病毒Ad5-P16及其应用 |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
WO2018085461A1 (en) | 2016-11-01 | 2018-05-11 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
GB201802539D0 (en) * | 2018-02-16 | 2018-04-04 | Univ College Cardiff Consultants Ltd | Modified adenoviruses |
US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
EP3844286A1 (en) | 2018-08-31 | 2021-07-07 | Orca Therapeutics B.V. | Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (gsk3) and methods of killing aberrant cells |
KR20220038485A (ko) | 2019-08-05 | 2022-03-28 | 메조블라스트 인터내셔널 에스에이알엘 | 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법 |
US20230293590A1 (en) | 2020-08-10 | 2023-09-21 | Mesoblast International Sárl | Cellular compositions and methods of treatment |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096718A (en) * | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
WO2004013302A2 (en) * | 2002-08-02 | 2004-02-12 | Phenomix, Inc. | CARD11 NFkB ACTIVATING POLYPEPTIDES, NUCLEIC ACIDS, INBRED AND TRANSGENIC ANIMALS, AND METHODS OF USE THEREOF |
CN1424401A (zh) * | 2003-01-06 | 2003-06-18 | 李川源 | 有条件复制型腺病毒及其构建方法和用途 |
WO2004101799A2 (en) * | 2003-05-14 | 2004-11-25 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Broadening adenovirus tropism |
CN101068933A (zh) * | 2004-08-25 | 2007-11-07 | 细胞基因***有限公司 | 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体 |
US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
-
2008
- 2008-03-12 EP EP08735417A patent/EP2137301B1/en active Active
- 2008-03-12 CA CA2680659A patent/CA2680659C/en active Active
- 2008-03-12 DK DK08735417.1T patent/DK2137301T3/da active
- 2008-03-12 PT PT08735417T patent/PT2137301E/pt unknown
- 2008-03-12 CN CN2008800082803A patent/CN101702918B/zh active Active
- 2008-03-12 AT AT08735417T patent/ATE510907T1/de active
- 2008-03-12 WO PCT/EP2008/052960 patent/WO2008110579A2/en active Application Filing
- 2008-03-12 ES ES08735417T patent/ES2367227T3/es active Active
- 2008-03-12 JP JP2009553138A patent/JP5746823B2/ja active Active
-
2009
- 2009-09-10 US US12/557,031 patent/US8974777B2/en active Active
-
2010
- 2010-11-04 HK HK10110333.3A patent/HK1143992A1/xx unknown
-
2014
- 2014-10-06 JP JP2014205985A patent/JP2015043777A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2137301B1 (en) | 2011-05-25 |
EP2137301A2 (en) | 2009-12-30 |
CA2680659C (en) | 2016-06-28 |
PT2137301E (pt) | 2011-09-02 |
US20100124546A1 (en) | 2010-05-20 |
CN101702918A (zh) | 2010-05-05 |
ES2367227T3 (es) | 2011-10-31 |
JP2010520762A (ja) | 2010-06-17 |
US8974777B2 (en) | 2015-03-10 |
CA2680659A1 (en) | 2008-09-18 |
WO2008110579A3 (en) | 2008-11-13 |
ATE510907T1 (de) | 2011-06-15 |
JP5746823B2 (ja) | 2015-07-08 |
DK2137301T3 (da) | 2011-09-12 |
CN101702918B (zh) | 2013-03-27 |
WO2008110579A2 (en) | 2008-09-18 |
JP2015043777A (ja) | 2015-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1143992A1 (en) | Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatment | |
AU2018256546A1 (en) | Combination therapy with peptide epoxyketones | |
MX2019001920A (es) | Arn la terapia contra el cancer. | |
HK1109638A1 (en) | Dr5 antibodies and uses thereof dr5 | |
EP2056818A4 (en) | COMPOSITIONS AND METHODS FOR NEUROPROTECTION | |
TW200637522A (en) | Skin treatment articles and methods | |
JO3235B1 (ar) | مركبات بيررولوبيريميدين و استعمالاتها | |
IL190796A0 (en) | Compositions and their uses for gene therapy of bone conditions | |
MX2009013729A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
MX2010005651A (es) | Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento. | |
MXPA05012421A (es) | Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos. | |
UA107667C2 (uk) | Лікарські сполуки, що модулюють активність піруваткінази-м2, композиції на їх основі та застосування при лікуванні раку | |
MX2009003362A (es) | Uso de interleucina-10 pegilada para tratamiento de cancer. | |
TW200612918A (en) | Lonidamine analogs | |
HK1112367A1 (en) | Survivin peptide vaccine | |
MY161656A (en) | Therapeutic use of diaminophenothiazines | |
MY146112A (en) | Long-term feed - cancer patient | |
MX2009005300A (es) | Combinacion de un inhibidor de acido desoxirribonucleico polimerasa-alfa y un inhibidor de una cinasa de punto de verificacion para trastornos proliferativos. | |
EP2214495A4 (en) | NATURALLY PHOTODYNAMIC ACTIVE SUBSTANCES AND ITS USE | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
JO3262B1 (ar) | توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان | |
UA99601C2 (ru) | Применение антитела к cd151 для лечения первичных опухолей | |
WO2007107748A3 (en) | Inhibition of tumour growth | |
WO2007130501A3 (en) | Combination therapy for treatment of cancer | |
EP1773363A4 (en) | NGNA COMPOSITIONS AND METHODS OF USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CORR | Corrigendum |
Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF 20131004: (72) |